Harmonic Discovery Announces Licensing Agreement with BioVentures and UCSF for FLT3 Mutated AML Development Program

Harmonic Discovery (the “Company”), a precision pharmacology company focusing on developing next generation kinase inhibitors, today announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia (AML) from BioVentures (University of Arkansas for Medical Sciences) and UC San Francisco (UCSF).

Rockland Launches Novel Analytical Tools to Assess Drug Delivery: Revolutionizing Oligonucleotide Therapeutic Development

The first and only panel of specialty reagents designed to detect PS modifications independent of sequence, format, or location, streamlining candidate triage for unparalleled cost and time savings in non-clinical/pre-clinical discovery assessment of oligonucleotide drug candidates, clinical trials for immunogenicity studies, and other applications.

American Dental Hygienists’ Association Partners with Colgate® for October’s National Dental Hygiene Month 2023

The ADHA® renews its partnership with Colgate® Oral Pharmaceuticals, Inc. for National Dental Hygiene Month 2023, to honor all dental hygienists throughout October. This year’s theme, “Everyday Extraordinary,” celebrates dental hygienists who transform everyday tasks with extraordinary expertise.

Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform today announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company for the Middle East and North Africa (MENA).

Massachusetts General Hospital Researchers and Prevencio Announce the Power of Artificial Intelligence HART® Platform for Medical Diagnostic Test Development

Prevencio, Inc. today announces the culminative presentation of patient data demonstrating that its Artificial Intelligence (AI)-driven HART® blood tests are highly accurate in a broad range of patients, including those suffering from diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic and may be used to develop diagnostics beyond cardiac disease.

CIHR chooses Digital Science to support discoveries for Canada’s health

Digital Science is pleased to announce that the Canadian Institutes of Health Research (CIHR) has chosen Altmetric and Dimensions from Digital Science’s flagship products to support its belief that research has the power to change lives.

New machine-learning simulations reduce energy need for mask fabrics, other materials

A new computational effort between Argonne and 3M promises to reduce energy consumption without sacrificing material quality in the production of nonwoven plastics, commonly used in surgical masks.

American Dental Hygienists’ Association Teams Up with Colgate® for National Dental Hygiene Month 2022

The American Dental Hygienists’ Association (ADHA®) is proud to announce its partnership with Colgate® Oral Pharmaceuticals, Inc. for National Dental Hygiene Month (NDHM) this October. This year’s focus is built on the theme of Empowerment.

La Jolla Institute for Immunology Acquires the Carterra LSA Platform to Advance State-of-the-Art Immunological and Infectious Disease Research

Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, and La Jolla Institute for Immunology (LJI), a globally recognized non-profit research organization dedicated to understanding the power of the immune system to promote human health, announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.

ORTHO RANKS NO.1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW

QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) announced today that its subsidiary, Ortho Clinical Diagnostics, a leading provider of in vitro diagnostics solutions and services to hospitals, clinical laboratories and blood banks around the world, has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2022 IMV ServiceTrak™ Awards for the fifth consecutive year. The ranking is based on interviews conducted with laboratory professionals, including Ortho’s customers, from more than 1,200 clinical testing locations operating over 1,900 collective instruments. The prestigious annual IMV ServiceTrak™ Awards rankings affirm the continued power and impact of Ortho’s innovative Ortho Care® Services and Informatics platform.